Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients with Parkinson’s Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications

June 02, 2021
https://clinicaltrials.gov/ct2/show/NCT04857359
Neurology
Principal Investigator: Peter A Le Witt, MD
Neurology, Movement Disorders, Parkinson's Disease, Dyskinesia